Michelle Holmer, MD
Family Medicine · Stow, OHNPI 1588640668
Payments from drug & device makers
Across 163 payments — averaging $12.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$282
- AstraZeneca$226
- Novartis$200
- Pfizer$171
- AbbVie$151
- Boehringer Ingelheim$113
- plus $817 from 24 others
What the payments were for
- Food & beverage$1,952100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $282 |
| AstraZeneca | 13 | $226 |
| Novartis | 14 | $200 |
| Pfizer | 20 | $171 |
| AbbVie | 16 | $151 |
| Boehringer Ingelheim | 9 | $113 |
| Astellas Pharma US Inc | 8 | $112 |
| Abbott | 5 | $90 |
| Lilly USA, LLC | 6 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $51 |
| Genentech USA, Inc. | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $45 |
| Merck | 3 | $40 |
| GSK | 3 | $37 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Dexcom, Inc. | 2 | $33 |
| Gilead | 2 | $30 |
| Shire North American Group Inc | 1 | $23 |
| Bayer | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Medtronic | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Amgen | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,960 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $110,014 |
| OzempicSemaglutide | 62 | $65,734 |
| JardianceEmpagliflozin | 31 | $44,478 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $22,645 |
| FarxigaDapagliflozin Propanediol | 19 | $22,223 |
| TrulicityDulaglutide | 25 | $22,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $20,429 |
| JanuviaSitagliptin Phosphate | 20 | $18,240 |
| MyrbetriqMirabegron | 14 | $15,504 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $9,369 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $6,553 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 15 | $6,210 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,738 |
| Atorvastatin Calcium | 425 | $3,859 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $171 | $110,014111 claims |
| Novo NordiskOzempic | $282 | $65,73462 claims |
| Boehringer IngelheimJardiance | $113 | $44,47831 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $37 | $43,07462 claims |
| AstraZenecaFarxiga | $226 | $22,22319 claims |
| Lilly USA, LLCTrulicity | $89 | $22,13925 claims |
| MerckJanuvia | $40 | $18,24020 claims |
| Astellas Pharma US IncMyrbetriq | $112 | $15,50414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $51 | $5,73812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Stow
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.